Current diagnosis and management of mucopolysaccharidosis VI in the Asia-Pacific region

Molecular Genetics and Metabolism

Volumn 107, Issue 1-2, 2012, Pages 136-144

  Hwu, Wuh Liang ^a   Okuyama, Torayuki ^b   But, Wai Man ^c   Estrada, Sylvia ^d,e,f   Gu, Xuefan ^g   Hui, Joannie ^h   Kosuga, Motomichi ^b   Lin, Shuan Pei ⁱ   Ngu, Lock Hock ^j   Shi, Huiping ^k   Tanaka, Akemi ^l   Thong, Meow Keong ^m   Wattanasirichaigoon, Duangrurdee ⁿ   Wasant, Pornswan ^o   McGill, Jim ^p  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^c QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^d UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^e PHILIPPINE GENERAL HOSPITAL   (Philippines)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^h CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

ⁱ MACKAY MEMORIAL HOSPITAL   (Taiwan)

^j HOSPITAL KUALA LUMPUR   (Malaysia)

^k PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^l OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^m UNIVERSITY OF MALAYA   (Malaysia)

ⁿ MAHIDOL UNIVERSITY   (Thailand)

^o MAHIDOL UNIVERSITY   (Thailand)

^p ROYAL CHILDREN'S HOSPITAL   (Australia)

more..

Author keywords

Arylsulfatase B gene (ARSB); Enzyme replacement therapy (ERT); Glycosaminoglycan (GAG); Mucopolysaccharidosis type VI (MPS VI)

Indexed keywords

GLYCOSAMINOGLYCAN; IDURONATE 2 SULFATASE; LARONIDASE;

ARTICLE; AUDIOMETRY; AUSTRALIA; BONE MARROW TRANSPLANTATION; CHINA; CHROMATOGRAPHY; CONSULTATION; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DISEASE REGISTRY; ELECTROCARDIOGRAM; ELECTROPHORESIS; ENZYME ASSAY; ENZYME REPLACEMENT; EYE EXAMINATION; FIBROBLAST; FLUOROMETRY; FOLLOW UP; GENETICIST; HEALTH CARE ACCESS; HEALTH INSURANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HONG KONG; HUMAN; JAPAN; LABORATORY TEST; LEUKOCYTE; LUNG FUNCTION TEST; MALAYSIA; MAROTEAUX LAMY SYNDROME; MASS SPECTROMETRY; MEDICAL SPECIALIST; MOLECULAR DIAGNOSIS; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOPEDIC SURGEON; PEDIATRICIAN; PHILIPPINES; PHYSICAL EXAMINATION; PLASMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RADIOGRAPHY; RANGE OF MOTION; SPECTROPHOTOMETRY; STRUCTURED QUESTIONNAIRE; SURGICAL TECHNIQUE; TAIWAN; THAILAND; TOLUIDINE BLUE SPOT; X RAY;

ASIA; AUSTRALIA; HEALTH CARE SURVEYS; HUMANS; MUCOPOLYSACCHARIDOSIS VI; PHYSICIANS; QUESTIONNAIRES;

EID: 84866154516     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2012.07.019     Document Type: Article

References (32)

1. Muenzer J. The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. J. Pediatr. 2004, 144:S27-S34.
2. Neufeld F., Muenzer J. The mucopolysaccharidoses. The Metabolic and Molecular Bases of Inherited Disease 2001, 3421-3452. McGraw-Hill, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
3. Giugliani R., Harmatz P., Wraith J.E. Management guidelines for mucopolysaccharidosis VI. Pediatrics 2007, 120:405-418.
4. Valayannopoulos V., Nicely H., Harmatz P., Turbeville S. Mucopolysaccharidosis VI. Orphanet J. Rare Dis. 2010, 5:5.
5. Pilz H., von F.K., Goebel H.H. Deficiency of arylsulfatase B in 2 brothers aged 40 and 38 years (Maroteaux-Lamy syndrome, type B). Ann. Neurol. 1979, 6:315-325.
6. Tonnesen T., Gregersen H.N., Guttler F. Normal MPS excretion, but dermatan sulphaturia, combined with a mild Maroteaux-Lamy phenotype. J. Med. Genet. 1991, 28:499-501.
7. Baehner F., Schmiedeskamp C., Krummenauer F., Miebach E., Bajbouj M., Whybra C., Kohlschutter A., Kampmann C., Beck M. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J. Inherit. Metab. Dis. 2005, 28:1011-1017.
8. Malm G., Lund A.M., Mansson J.E., Heiberg A. Mucopolysaccharidoses in the Scandinavian countries: incidence and prevalence. Acta Paediatr. 2008, 97:1577-1581.
9. Wasant P. Inherited metabolic disorders in Thailand and the Asia-Pacific. Genomics and Health in the Developing World 2012, Oxford University Press USA, NY USA. D. Kumar (Ed.).
10. Swiedler S.J., Beck M., Bajbouj M., Giugliani R., Schwartz I., Harmatz P., Wraith J.E., Roberts J., Ketteridge D., Hopwood J.J., Guffon N., Sa Miranda M.C., Teles E.L., Berger K.I., Piscia-Nichols C. Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am. J. Med. Genet. A 15 4 2005, 134A:144-150.
11. Meikle P.J., Hopwood J.J., Clague A.E., Carey W.F. Prevalence of lysosomal storage disorders. JAMA 20 1 1999, 281:249-254.
12. Nelson J., Crowhurst J., Carey B., Greed L. Incidence of the mucopolysaccharidoses in Western Australia. Am. J. Med. Genet. A 15 12 2003, 123A:310-313.
13. Lin H.Y., Lin S.P., Chuang C.K., Niu D.M., Chen M.R., Tsai F.J., Chao M.C., Chiu P.C., Lin S.J., Tsai L.P., Hwu W.L., Lin J.L. Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004. Am. J. Med. Genet. A 2009, 149A:960-964.
14. Lee H.J. Inborn errors of metabolism in Korea. J. Korean Neurol. Assoc. 2004, 22:1-10.
15. Nor A., Zabedah M.Y., Norsiah M.D., Ngu L.H., Suhaila A.R. Separation of sulfated urinary glycosaminoglycans by high-resolution electrophoresis for isotyping of mucopolysaccharidoses in Malaysia. Malays J. Pathol. 2010, 32:35-42.
16. Zhang H.W., Wang Y., Ye J., Qiu W.J., Han L.S., Gao X.L., Gu X.F. Enzymatic diagnosis of 47 cases with mucopolysaccharidosis. Zhonghua Er Ke Za Zhi 2009, 47:276-280.
17. Sohn W.Y., Lee J.H., Paik K.H., Kwon E.K., Kim A.H., Jin D.K. Clinical and laboratory features of Korean mucopolysaccharidosis (MPSs). Korean J. Pediatr. 2005, 48:1132-1138.
18. Malatack J.J., Consolini D.M., Bayever E. The status of hematopoietic stem cell transplantation in lysosomal storage disease. Pediatr. Neurol. 2003, 29:391-403.
19. Turbeville S., Nicely H., Rizzo J.D., Pedersen T.L., Orchard P.J., Horwitz M.E., Horwitz E.M., Veys P., Bonfim C., Al-Seraihy A. Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VI. Mol. Genet. Metab. 2011, 102:111-115.
20. Harmatz P., Giugliani R., Schwartz I., Guffon N., Teles E.L., Miranda M.C., Wraith J.E., Beck M., Arash L., Scarpa M., Yu Z.F., Wittes J., Berger K.I., Newman M.S., Lowe A.M., Kakkis E., Swiedler S.J. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J. Pediatr. 2006, 148:533-539.
21. Harmatz P., Giugliani R., Schwartz I.V., Guffon N., Teles E.L., Miranda M.C., Wraith J.E., Beck M., Arash L., Scarpa M., Ketteridge D., Hopwood J.J., Plecko B., Steiner R., Whitley C.B., Kaplan P., Yu Z.F., Swiedler S.J., Decker C. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol. Genet. Metab. 2008, 94:469-475.
22. Horovitz D.D.G., Magalhes T., Costa A.P., Carelli L.E., Silva D.S., de Linhares e Riello A.P.F., Llerena J. Spinal cord compression in young children with type VI mucopolysaccharidosis. Mol. Genet. Metab. 2011, 104:295-300.
23. Mucopolysaccharidosis Disease Advisory Committee Guidelines for the treatment of mucopolysaccharidosis Type VI (MPS VI) disease through the Life Saving Drugs Program Anonymous. http://www.health.gov.au/internet/main/publishing.nsf/Content/lsdp-info/$File/MPSVI.pdf.
24. McGill J.J., Inwood A.C., Coman D.J., Lipke M.L., de Lore D., Swiedler S.J., Hopwood J.J. Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age-a sibling control study. Clin. Genet. 2010, 77:492-498.
25. Lin H.Y., Chen M.R., Chuang C.K., Chen C.P., Lin D.S., Chien Y.H., Ke Y.Y., Tsai F.J., Pan H.P., Lin S.J., Hwu W.L., Niu D.M., Lee N.C., Lin S.P. Enzyme replacement therapy for mucopolysaccharidosis VI-experience in Taiwan. J. Inherit. Metab. Dis. 2011, 34:241.
26. Scarpa M., Barone R., Fiumara A., Astarita L., Parenti G., Rampazzo A., Sala S., Sorge G., Parini R. Mucopolysaccharidosis VI: the Italian experience. Eur. J. Pediatr. 2009, 168:1203-1206.
27. Azevedo A.C.M.M., Schwartz I.V., Kalakun L., Brustolin S., Burin M.G., Beheregaray A.P.C., Leistner S., Giugliani C., Rosa M., Barrios P., Marinho D., Esteves P., Valadares E., Boy R., Horovitz D., Mabe P., Da Silva L.C.S., De Souza I.C.N., Ribeiro M., Martins A.M., Palhares D., Kim C.A., Giugliani R. Clinical and biochemical study of 28 patients with mucopolysaccharidosis type VI. Clin. Genet. 2004, 66:208-213.
28. Fuller M., Tucker J.N., Lang D.L., Dean C.J., Fietz M.J., Meikle P.J., Hopwood J.J. Screening patients referred to a metabolic clinic for lysosomal storage disorders. J. Med. Genet. 2011, 48:422-425.
29. Bagewadi S., Roberts J., Mercer J., Jones S., Stephenson J., Wraith J.E. Home treatment with elaprase and naglazyme is safe in patients with mucopolysaccharidoses types II and VI, respectively. J. Inherit. Metab. Dis. 2008, 31:733-737.
30. Tifft C., Proud V., Levy P., DeMarco K., Nicely H., Turbeville S. Enzyme replacement therapy in the home setting for mucopolysaccharidosis VI: a survey of patient characteristics and physicians' early findings in the United States. J. Infus. Nurs. 2009, 32:45-52.
31. Auclair D., Hopwood J.J., Brooks D.A., Lemontt J.F., Crawley A.C. Replacement therapy in mucopolysaccharidosis type VI: advantages of early onset of therapy. Mol. Genet. Metab. 2003, 78:163-174.
32. Furujo M., Kubo T., Kosuga M., Okuyama T. Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI. Mol. Genet. Metab. 2011, 104(4):597-602.